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Background: Unfractionated heparin (UFH) is widely used as a reversible anti-coagulant in cardiopulmonary bypass
(CPB). However, the pharmacokinetic characteristics of UFH in CPB surgeries remain unknown because of the lack of
means to directly determine plasma UFH concentrations. The aim of this study was to establish a pharmacokinetic
model to predict plasma UFH concentrations at the end of CPB for optimal neutralization with protamine sulfate.
Methods: Forty-one patients undergoing CPB during cardiac surgery were enrolled in this observational clinical study
of UFH pharmacokinetics. Patients received intravenous injections of UFH, and plasma anti-FIIa activity was measured
with commercial anti-FIIa assay kits. A population pharmacokinetic model was established by using nonlinear mixed-effects
modeling (NONMEM) software and validated by visual predictive check and Bootstrap analyses. Estimated parameters in
the final model were used to simulate additional protamine administration after cardiac surgery in order to eliminate
heparin rebound. Plans for postoperative protamine intravenous injections and infusions were quantitatively
compared and evaluated during the simulation.
Results: A two-compartment pharmacokinetic model with first-order elimination provided the best fit. Subsequent
simulation of postoperative protamine administration suggested that a lower-dose protamine infusion over 24 h may
provide better elimination and prevent heparin rebound than bolus injection and other infusion regimens that have
higher infusion rates and shorter duration.
Conclusion: A two-compartment model accurately reflects the pharmacokinetics of UFH in Chinese patients during
CPB and can be used to explain postoperative heparin rebound after protamine neutralization. Simulations suggest a
24-h protamine infusion is more effective for heparin rebound prevention than a 6-h protamine infusion.
Keywords: Cardiopulmonary bypass, Cardiac surgery, Pharmacokinetic model, Unfractionated heparinBackground
Unfractionated heparin (UFH) is an anionic mixture of
highly sulfated linear glucosamine-glycans with varying
molecular weights (3–30 kD) [1,2]. The anti-coagulation
effect of heparin is dependent upon binding with the
serine protease inhibitor anti-thrombin III (ATIII) [3].
Binding with ATIII increases the inhibitory activity of
ATIII against both thrombin (FIIa) and factor Xa (FXa) and
other serine proteases in the coagulation cascade by over* Correspondence: Xt.hou@ccmu.edu.cn
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unless otherwise stated.1000-fold [2,4]. Human FIIa is much more sensitive than
FXa to inhibition mediated by the heparin-ATIII complex,
so the anti-FIIa assay may have a smaller lower limit of
quantitation (LLOQ) [5]. We measured anti-FIIa activity as
an index to quantify plasma UFH levels in humans [6].
The UFH half-life is 1–2 h in human plasma, depend-
ing on dose [2], as higher doses produce a prolonged
half-life due to the mechanism of plasma clearance,
which involves rapid distribution via UFH binding to
plasma proteins and receptors on endothelial cells and
macrophages, followed by slower elimination through
the kidneys [5]. Thus, UFH pharmacokinetics may include
a “peripheral process” by which the UFH molecule is con-
verted from the free to the bound state. Moreover, plasmais an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of patients
Characteristic Unit Number or mean (range)
Number of patients / 41
Body weight kg 66 (41–82)
Sex / Females: 19 Males: 13
Age Years 53.4 (18–74)
CPB time Hours 2.04 (0.95–3.29)
Dose of UFH in priming fluid
before CPB
IU 8516 (6250–10000)
First dose of UFH IU 24805 (18750–31250)
Total dose of UFH IU 34023 (25000–45000)
Jia et al. Journal of Translational Medicine  (2015) 13:45 Page 2 of 11UFH concentrations may exhibit larger inter-individual
variability than other anti-coagulation drugs.
UFH is widely utilized in cardiac surgery to achieve ad-
equate anti-coagulation and to restore normal hemostasis
during and after CPB. UFH anti-coagulation can be reversed
through formation of a stable complex with the highly cat-
ionic protamine sulfate, although its use as a ‘neutralizer’ of
UFH carries some risk. Rapid administration of protamine
sulfate can cause life-threatening hemodynamic disturbances
such as systemic arterial hypotension and pulmonary hyper-
tension, along with histamine release and hypoxemia, espe-
cially at the end of CPB when the myocardium is recovering
from ischemic insult [2,7,8]. Complete reversal of UFH anti-
coagulation is typically achieved with an excessive dose of
protamine sulfate, although this has been associated with
increased bleeding and inhibition of platelet glycopro-
tein Ib-von Willebrand factor, increased expression of
P-selectin, blockade of calcium-release channels, and
negative inotropic effects [2,9]. Accurate protamine dos-
ing requires an understanding of real plasma UFH levels.
However, the pharmacokinetic profile of UFH is unknown
for Asian patients undergoing CPB.
Since 1962, Hyun and other researchers have used the
phrase “heparin rebound” to describe the reappearance of
UHF in circulating blood even after a dose of excess protam-
ine sulfate [10,11]. Teoh et al. postulated that heparin re-
bound could be due to a portion of UFH administered
during surgery that remains protein-bound and does not
form a complex with protamine sulfate; these complexes dis-
sociate slowly to produce anticoagulant effects [12]. No quan-
titative studies of this phenomenon have been published.
The objective of this study was to quantitate the phar-
macokinetic characteristics of UFH in Chinese patients
undergoing CPB, characterize the correlation between
heparin rebound and UFH pharmacokinetics, and estab-
lish a pharmacokinetic model. The model can be used to
simulate and optimize protamine sulfate dosing in order
to minimize the side effects of protamine sulfate and re-
store normal hemostasis with minimal post-operative
bleeding and blood transfusion.
Methods
Patients
After subjects with dysfunctions of the kidney, liver, or
blood coagulation were excluded, 41 study patients under-
went CPB during cardiac surgery (Table 1). The study
protocol was approved by the Ethics Committee of Capital
Medical University (Beijing, China). All subjects provided
written informed consent prior to enrollment.
Experimental design
Subjects had received an initial intra-venous injection of
UFH (Changzhou Qianhong Biopharma, Changzhou,
China) at 375 IU/kg (3 mg/kg; 1 mg = 125 IU) beforeCPB. Ten minutes after the initial dose, the first blood
sample was collected from the jugular vein. The CPB
pipelines were primed with 1500 mL of balanced solu-
tion and a second UFH dose (1 mg/kg). The CPB flow
was maintained at 2.2–2.4 L/min/m2 with gravity siphon
venous drainage. The temperature of the CPB system
drifted to 32°C. The targeted mean perfusion pressure
was 50–70 mmHg. Myocardial preservation was achieved
with blood cardioplegic solution; ultrafiltration was
avoided throughout the operation. A series of irregular
UFH intravenous injections were administered, depending
on each patient’s blood coagulation activity during CPB.
Before UFH neutralization with protamine sulfate, sam-
pling was performed at 30-min intervals. All samples were
collected in 3-mL vacuum tubes buffered with sodium cit-
rate and stored immediately at 4°C. Stored blood samples
were centrifuged (2000 × g, 15 min) within 24 h of collection
to remove platelets and hemocytes. Platelet-poor plasma
(PPP) was then collected and stored at −80°C. The actual
UFH dosing time and dosages of were recorded carefully.
After UFH neutralization, the sampling schedule was
2, 4, 8, 12, and 24 h. Actual sampling times deviated
slightly from the schedule, so only the actual sampling
times were documented.
Sample dilution and determination of anti-FIIa activity
The actual anti-FIIa activity in plasma during CPB is much
larger than the measurable range (0.0–0.6 IU/mL for the
anti-FIIa assay). Thus, samples collected before protamine
neutralization were diluted with Normal Pooled Platelet-
poor plasma (NPPPP) at 1:29. NPPPP was derived from
PPP collected from 20 randomly selected healthy adults.
Twenty parts of plasma were centrifuged separately (2000
x g, 15 min, at room temperature) to remove platelets,
then were mixed into a single-part NPPPP.
Anti-FIIa activities in plasma were determined as re-
ported by Falkon et al. [13,14]. All assays were per-
formed on an ACL-TOP automated coagulation assay
platform (Instrumentation Laboratory, Orangeburg, NY).
The Heparin Chromogenic Activity Kit 820 (American
Diagnostica, Stamford, CT) was used for the anti-FIIa assay.
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NONMEM (version VII, level 2.0; Icon Development
Solutions, Hanover, MD) was used to establish the
pharmacokinetic model, with gFORTRAN (version 4.0)
as the FORTRAN compiler and platform R (version
2.15.0) as the statistical and plotting software. All model-
ing and simulation procedures were performed on an op-
erative platform for NONMEM known as “Perl speaks
NONMEM” (PsN; version 3.4.0). First-order conditional
estimation (FOCE) was the chosen algorithm. Results
with p < 0.01 were considered significant.
Our data involved a series of post-neutralization points
indicating heparin rebound, which cannot be explained
by a mono-compartment model. Thus, the base model
that provided the best data fit was a two-compartment
model with first-order elimination and multiple irregular
intravenous administration of UFH (Figure 1).
The base model was a typical two-compartment model
with multiple dosing during surgery. However, due to injec-
tion of excessive protamine sulfate, the amount of UFH in
the central compartment was supposed to be instantly
cleared. Thus, XUFH-C was set to 0 at that time, whereas the
amount of UFH in the peripheral compartment remained
unaffected. Distribution to the central compartment followed
the inverse pattern, as the amount of UFH in the central
compartment increased from 0. These assumptions were
used to describe UFH neutralization with excess protamine
sulfate and heparin rebound after neutralization.
In Figure 1, XUFH-C and XUFH-P are represent the
amounts of UFH in central and peripheral compartments,
whereas VUFH-C and VUFH-P and are the apparent volumes
of distribution for the central and peripheral compart-
ments, respectively; K10 is the first-order elimination rate
constant; K12 and K21 and are the first-order rateFigure 1 Two-compartment model with intravenous injection
and first-order elimination. XUFH-C and XUFH-P represent the
amount of UFH in central and peripheral compartments respectively;
VUFH-C and VUFH-P are the apparent volumes of distribution for the
central and peripheral compartments respectively.constants of the transportations of UFH from the central
to the peripheral compartment and from the peripheral to
the central compartment, respectively.
The original differential equations corresponding to the
two-compartment model with single intravenous administra-
tion and first-order elimination are given in Eq. 1 and Eq. 2.
dXUFH−C
dt
¼ K21XUFH−P−K12XUFH−C−K 10XUFH−C ð1Þ
dXUFH−P
dt
¼ −K21XUFH−P þ K 12XUFH−C ð2Þ
The initial condition: t = 0, XUFH −C =Dinj, XUFH − P = 0,
where t is time, and Dinj is the injected dose of UFH. To
be more intuitive, we excluded the algebraic steps, and
the Laplace-transformed equations of integral form are
given by Eq. 3, 4, 5, 6.
α ¼
K 10 þ K 12 þ K 21ð Þ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ





K 10 þ K 12 þ K 21ð Þ−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




XUFH−C ¼ f 1 tð Þ ¼
α−K 21ð ÞDinje−αt þ K 21−βð ÞDinje−βt
α−β
ð5Þ




Thus, we have the following equation representing the
time-sequence function of the plasma UFH level, shown in
Eq. 7:
CUFH−C ¼ f 3 tð Þ ¼
α−K21ð ÞDinje−αt þ K 21−βð ÞDinje−βt
α−βð Þ V=Fð Þ ð7Þ
Irregular intra-venous injection of UFH could be ad-
ministered when there was a risk of blood coagulation
during CPB. Thus, the equations representing the model
of a single intravenous injection of UFH (Eq. 5, 6, 7)
were updated for multiple irregular intravenous injec-
tions of UFH, which is given by Eq. 8–10 a according to
the “superposition principle” of linear systems.
XUFH−C ¼ g1 tð Þ ¼
Xn
i¼1
α−K 21ð ÞDie−α t−τið Þ þ K 21−βð ÞDie−β t−τið Þ
α−β
ð8Þ
XUFH−C ¼ g1 tð Þ ¼
Xn
i¼1
α−K 21ð ÞDie−α t−τið Þ þ K 21−βð ÞDie−β t−τið Þ
α−β
ð9Þ
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Xn
i¼1
α−K21ð ÞDie−α t−τið Þ þ K 21−βð ÞDie−β t−τið Þ
α−βð Þ V=Fð Þ
ð10Þ
Where τi is the time of the i
th administration of
UFH; Di is the dose of the i
th administration of UFH;
and the maximum number of UFH doses is counted
as n.
The amount of UFH in the central compartment must
clear instantly when protamine sulfate is administered
for neutralization. To describe such a situation after
neutralization or the post-CPB pharmacokinetics of
UFH mathematically, the initial conditions of the dif-
ferential equations (Eq. 1–2) mentioned above were re-
set to t = Tneu, XUFH − C = 0, XUFH − P = g2(Tneu), where
Tneu represents the time of neutralization using pro-
tamine sulfate, and the function g2 represents Eq. 9.
Then Eq. 5–7, representing the amounts of UFH in the
central and peripheral compartments as well as the
plasma UFH level, were updated under new initial con-
ditions, resulting in Eq. 11, 12, 13:XUFH−C ¼ h1 tð Þ ¼
g2 Tneuð Þ α−K 21ð Þ β−K 21ð Þ e β−K12−K21−K10ð Þ t−Tneuð Þ−e α−K12−K21−K10ð Þ t−Tneuð Þ
 
K12 α−βð Þ ð11Þ
XUFH−P ¼ h2 tð Þ ¼




CUFH−C ¼ h3 tð Þ ¼
g2 Tneuð Þ α−K 21ð Þ β−K 21ð Þ e β−K12−K21−K10ð Þ t−Tneuð Þ−e α−K12−K21−K10ð Þ t−Tneuð Þ
 
K12 α−βð Þ V=Fð Þ ð13ÞThus, the overall time sequence function of plasma
UFH during and after CPB should combine Eq. 10 and
Eq. 13, as follows: and together, as described below:Ct ¼
g3 tð Þ ¼
Xn
i¼1
α−K21ð ÞDie−α t−τið Þ þ K 21−ð
α−βð Þ V=Fð Þ
h3 tð Þ ¼
g2 Tneuð Þ α−K21ð Þ β−K21ð Þ e β−K12−K21−K10ð Þð

K12 α−βð Þ V=Fð
8>><
>>:As shown in Eq. 14, the pharmacokinetics of UFH
comprised two mathematically different stages. To
have a simple iteration step and a short computation
time and, most importantly, to set the amount of
UFH in the central compartment as 0 at the time of
neutralization, the Laplace-transformed equation (Eq. 14)
along with the $PRED block in NONMEM was used in
the computation process.
During computation, h1–3(t) and g1–3(t) were cal-
culated simultaneously, and their real-time values
documented automatically by NONMEM. At the
time of neutralization, the value of XUFH − C was in-
stantly set to 0, whereas the value of XUFH − P at that
moment was documented automatically as the new
initial condition of the inverse distribution of UFH
from the peripheral compartment towards the cen-
tral compartment.
Population pharmacokinetic modeling involves ran-
dom effects and fixed effects [15]. In this study, the
random effects were interindividual and residual. The
inter-individual random effects were analyzed using
an exponential model (Eq. 15), whereas the residualβÞDie−β t−τið Þ when 0≤t < Tneu
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(Eq. 16):
Pi ¼ Ppop: eηi ð15Þ
Where Pi is the pharmacokinetic parameter of the i
th
individual; Ppop is the typical population parameter; ηi is
the inter-individual variability of the ith individual, fol-
lowing a normal distribution of N(0, ω2)
Cpred ¼ XUFH−CVUFH−C
Cobs ¼ Cpred : 1þ ε1ð Þ þ ε2
8<
: ð16ÞFigure 2 Anti-FIIaactivityvs. Time. A, Anti-FIIa activity vs. time for blood sam
obtained no less than24 h after the end of CPB (n = 32). In both plots, the timIn Eq. 16, Cobs is the observed plasma concentration,
Cpred is the predicted plasma concentration, and ε1 and
ε2 define the proportional error and additional error,




Continuous fixed effects (age, body weight) were
analyzed in the pharmacokinetic model in a linear
manner:
Pi ¼ Ppop : 1 θCOV : COV −COV ið Þð Þ : eηi ð17Þples obtained during CPB. B, anti-FIIa activity vs. time for blood samples
e at the start of CPB was set to 0.
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pharmacokinetic parameters, θCOV is the influence co-
efficient of the given fixed effect, and COV and COV i are
the mean and individual values of the fixed effect.
Discontinuous fixed effects (e.g. sex) were analyzed in
the pharmacokinetic model in a conditional manner:
Pi ¼ Ppop: eηi: θGNDR ð18ÞFigure 3 Basic goodness-of-fit plots of the final population pharma
concentrations. B: observed vs. individual predicted concentrations. C: c
concentrations. D: conditional weighted residuals vs. time after first dose
(OLS) method.Where GNDR is the value of represents sex (0 for
male, 1 for female). θ is the influence coefficient of
sex. θGNDR equals 1 for males and θ when it is for
females.
Covariate analysis was performed by a stepwise re-
gression known as “forward inclusion” and “backward
elimination”. In forward modeling, all covariates were
added to the base model, one after the other. Then, allcokinetic model. A: observed vs. population predicted
onditional weighted residuals vs. population predicted
. The red line represents the linear fit by the ordinary least square
Table 2 Estimates of the parameters of the final model
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value (OFV) over 6.63 (x2 distribution with 1df for p < 0.01)
were listed in descending order according to the decrease in
OFV. All remaining covariates were again added to the
base model in order. If the OFV reduction was over
6.63 (p < 0.01), the covariate was retained. Otherwise,
it was ruled out until no further reduction of the OFV
occurred (full model).
In backward modeling, all covariates in the full model
were removed one at a time. Only covariates with sufficient
contributions to the prediction of the pharmacokinetic
model were retained based on an increase in the OFV
greater than 10.83 (p < 0.001). Otherwise, the covariate was
ruled out until no further increase of the OFV occurred
(final model).
Model validation
The basic goodness-of-fit plots, including population
predicted concentration (PRED) vs. observed concentration
(OBS) plot, individual predicted concentration (IPRED) vs.
OBS plot, conditional weighted residuals (CWRES) vs.
PRED plot, and CWRES vs. time plot, were used to evaluate
the final model.
The bootstrap method was used to evaluate accuracy
and stability. The original dataset was re-sampled ran-
domly 1000 times, producing 1000 new datasets. The
final model was recalculated for the new datasets, and
the median value and 90% confidence intervals of the
recalculated model parameters compared to the final
model.
The visual predictive check (VPC) method was used to
evaluate the accuracy and predictive ability of the final
model. The final model with the original dataset was
simulated 1000 times with different random seeds, and
the 5%, 50%, and 95% fractiles along with the 90% confi-
dence interval of 1000-fold simulation compared to the
observed data.
We also simulated the administration of excess pro-
tamine via bolus injection or infusions to determine
which provides minimal heparin rebound after CPB.
Simulations were performed with NONMEM and the
results compared to identify the optimal treatment for
heparin rebound.
Results
Thirty-two patients completed the clinical study. Total
administered UFH dose was about 33000 IU/surgery.
The change in anti-FIIa during CPB and 24 h after the
end of CPB is shown in Figure 2.
The model was parameterized in terms of volume of
distribution and clearance rather than rate constants.
The inter-individual random effect was evaluated with
an exponential error model and the intra-individual ran-
dom effect was evaluated with a hybrid model, involvingadditive and proportional errors. The fixed effects of
covariates were tested (age, body weight, sex) with for-
ward modeling and backward elimination methods.
None of the tested covariates significantly decreased
the objective function, and thus did not improve the
fit. The goodness-of-fit plots of the final model are
shown in Figure 3; estimates of the pharmacokinetic
parameters of the final model along with the results of
Bootstrap analyses are listed in Table 2.
The final model was validated with Bootstrap and
VPC. Bootstrap analyses showed a success rate of
57.3% (573 out of 1000 were successful in covariance
steps, whereas 982 out of 1000 were successful in
minimization). Parameter distribution in Bootstrap
analyses is summarized in Figure 4 and the VPC result
shown in Figure 5. Simulated plasma Anti-FIIa activities of
a hypothetical individual whose pharmacokinetic parame-
ters were identical to the parameter estimations in our
final model are shown in Figure 6.Discussion
The results suggested that UFH (375 IU/kg) adminis-
tered during CPB follows a two-compartment distri-
bution and first-order elimination curve with an
approximate initial half-life of 90 min. Median plat-
eau anti-FIIa activity during CPB was 2–19 IU/mL
(Figure 5), which was within the therapeutic range of
Figure 4 Distributions of the OFV and key parameters in bootstrap analyses. A: OFV; B: CL/F; C: VUFH-C in Bootstrap analyses; D: Q/F;
E: VUFH-P.
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exhibit very large interindividual differences. The me-
dian anti-FIIa level at the end of CPB was 4.8 IU/mL
and was neutralized with a mean 2.04 h after the start
of CPB. A heparin-rebound peak of 0.04 IU/mL was
attained 8 h after the end of CPB and was maintainedabove 0.02 IU/mL 24 h after neutralization, evidence
of heparin rebound.
Based on patient plasma UFH levels, a population
pharmacokinetic model was established using NON-
MEM. According to the goodness-of-fit plots in Figure 3,
CWRES seems to be distributed randomly between −4
Figure 5 VPC plots of the final model. A: before protamine neutralization; B: post-CPB VPC. Blue-colored areas are the 90% CI and pink-colored
areas are the 50% CI for simulated concentrations. The red line represents the median of the observed concentration; the dashed lines represent
the upper and lower 90% CI of observed concentrations.
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tions vs. observations were distributed along the y = x
line, suggesting that our final model was not biased and
was consistent.
Continuous infusion of protamine (25 mg/h) after
CPB can reduce the severity of post-operative heparin
rebound [4]. Thus, for a better illustration of our final
model and to test its clinical utility, we simulated the
plasma Anti-FIIa activities of a hypothetical individual
whose pharmacokinetic parameters were identical to
the parameter estimations in our final model. That is,
under hypothetical situations, continuous protamine
infusions at 25 mg/h lasting 6–24 h were adminis-
tered after CPB. The result of this simulation was
similar to prior reports (Figure 6) [4]. A comparison
of plots A and E suggest a 6-h infusion would de-
crease the plasma heparin levels caused by heparin re-
bound. A 24-h infusion would provide even better
control.
Most studies on UFH pharmacokinetics have been
based on measuring anti-coagulation activity as repre-
sented by the activated partial thromboplastin time or
activated coagulation time in plasma or whole blood.
Such methods are unstable, have poor reproducibility
across assays and, most importantly, can be used only
to monitor plasma UFH levels during or after CPB
[17-20]. In our study, patient plasma levels of UFH
were monitored during and after CPB using anestablished anti-FIIa assay [21,22]. Heparin rebound
could be caused by the inverse distribution of UFH
from the peripheral compartment to the central com-
partment. Therefore, additional administration of pro-
tamine after CPB could reduce the intensity and
duration of post-CPB heparin rebound.
To our knowledge, this is the first report of a UFH
pharmacokinetic model for CPB surgery; the model
can predict UFH concentrations at the end of CPB to
guide optimal neutralization with protamine sulfate.
Study limitations include the fact that only anti-FIIa
activity was monitored and UFH metabolites were
not studied, which means the roles of LMWH in
heparin rebound and during CPB remain unknown.
In addition, the study patients were given several
concomitant drugs that may also have affected
coagulation.Conclusions
A two-compartment model demonstrates the precise
pharmacokinetics of UFH in Chinese patients during
CPB and explains the postoperative heparin rebound
after protamine neutralization. A 24-h protamine infu-
sion is more effective than the 6-h infusion method for
reducing plasma heparin levels caused by heparin
rebound.
Figure 6 Simulated plots of infusion times and a protamine infusion rate of 25 mg/h. A: 6-h infusion; B: 8-h infusion; C: 12-h infusion;
D: 16-h infusion; E: 24-h infusion. Blue lines are simulated concentrations of UFH without follow-up protamine infusions or doses. Red lines
denote simulated concentrations of UFH over different protamine infusion times.
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